FDA Approves Merck’s Symptomatic Heart Failure Drug
Verquvo is a soluble guanylate cyclase stimulator for the reduction of the risk of cardiovascular death and heart failure hospitalization in adults with symptomatic chronic heart failure.
Merck, known as MSD outside the United States and Canada, announced on Jan. 20, 2021 that FDA has approved Verquvo, its soluble guanylate cyclase stimulator for the reduction of the risk of cardiovascular death and heart failure hospitalization in adults with symptomatic chronic heart failure.
The approval was based on positive data from a randomized, parallel-group, placebo-controlled, double-blind, event-driven, multi-center trial that compared the drug to a placebo in more than 5000 participants with symptomatic chronic heart failure, Merck said in a company press release. Verquvo proved to be more effective than the placebo in reducing the risk of cardiovascular death or heart failure hospitalization based on a time-to-event analysis.
“Verquvo has been shown to reduce the risk of cardiovascular death and heart failure hospitalization following a hospitalization for heart failure or need for outpatient IV [intravenous] diuretics. We are pleased to offer a meaningful new treatment option for appropriate patients with symptomatic chronic heart failure,” said Dr. Roy Baynes, senior vice-president and head of global clinical development, chief medical officer, Merck Research Laboratories, in the press release. “This approval builds upon Merck’s proud history of developing therapies for the treatment of patients with cardiovascular disease.”
Source: Merck
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
